The ability of biotech companies to efficiently use financial and commercial resources reflects their maturity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
As products enter clinic...scientists shown the door.
Nasdaq dilutes its biotech index
Related external links
Rights and permissions
About this article
Cite this article
Ratner, M. Maturing biotechs turn to pharma's markets. Nat Biotechnol 23, 269 (2005). https://doi.org/10.1038/nbt0305-269
Issue date:
DOI: https://doi.org/10.1038/nbt0305-269
This article is cited by
-
Earlier stage biotechs attract partners
Nature Biotechnology (2005)
-
Next-generation monoclonals less profitable than trailblazers?
Nature Biotechnology (2005)